

Please make the following amendments to the claims:

1-5 (canceled)

6. (currently amended) The polynucleotide ligand of ~~Claim 8~~ Claim 10, wherein said RNA polynucleotide ligand comprises 2-amino pyrimidine nucleotides.

7-9. (canceled)

10. (previously presented) A polynucleotide ligand comprising the sequence set forth in SEQ ID NO:12.

11. (canceled)

12. (currently amended) The polynucleotide ligand composition of ~~Claim 8~~ Claim 10, further comprising a pharmaceutically acceptable carrier.

13. (currently amended) The polynucleotide ligand composition of Claim 12, wherein said polynucleotide ligand composition comprises two or more polynucleotides comprising distinct sequences.

14-15 (canceled)

16. (currently amended) The method of ~~Claim 15~~ Claim 23, wherein said antiviral polynucleotide blocks viral entry into a cell.

17-18 (canceled)

19. (currently amended) The method of ~~Claim 15~~ Claim 23, wherein said RNA polynucleotide ligand comprises 2-amino pyrimidine nucleotides.

20-22. (canceled)

23. (currently amended) ~~The method of Claim 15,~~ A method of treating human cytomegalovirus infection, the method comprising:

administering a dose of an RNase resistant RNA polynucleotide ligand composition at a dose sufficient to decrease said cytomegalovirus infection, wherein said polynucleotide ligand comprises the sequence set forth in SEQ ID NO:12.

24. (canceled)

25. (currently amended) The method of ~~Claim 15~~ Claim 23, wherein said polynucleotide ligand composition comprises two or more polynucleotides comprising distinct sequences.

26. (canceled)